GHK-Cu Peptide: What It Is, How It Works and What the Research Shows

GHK-Cu is a copper peptide: the naturally occurring tripeptide glycine-histidine-lysine bound to a copper(II) ion. It was first identified in human serum in 1973. Preclinical research investigates its role in extracellular matrix remodeling, collagen and glycosaminoglycan synthesis, and connective tissue repair in cell culture and animal models. Available for laboratory research only.

Key research findings

• It’s a copper-binding tripeptide. Glycine-histidine-lysine bound to a copper(II) ion, first identified in human serum in 1973 (Pickart and Thaler, 1973).
• It binds copper selectively. Work published in 1980 found it complexed with copper and iron in plasma and proposed it as a copper transport factor (Pickart and Thaler, 1980; Pickart et al., 1980).
• Collagen synthesis rose in fibroblast cultures, at picomolar to nanomolar concentrations and independent of cell number (Maquart et al., 1988).
• Connective tissue accumulation increased in rat wound models in vivo (Maquart et al., 1993). The evidence is mostly preclinical. GHK-Cu isn’t approved by the FDA as a drug for any indication.

What is GHK-Cu?

GHK-Cu is the tripeptide glycine-histidine-lysine bound to a copper(II) ion. The GHK peptide on its own is just those three amino acids joined in a chain, and the bound copper is why GHK-Cu is called a copper peptide. You’ll also see it listed as copper tripeptide-1 on cosmetic ingredient labels.

Other names include Cu-GHK, prezatide copper, GHK copper peptide and the full chemical name, glycyl-L-histidyl-L-lysine copper complex. Search all of them when you’re reading the literature, or you’ll miss papers.

Attribute	Detail
Full name	Glycyl-L-histidyl-L-lysine copper complex
Sequence	Gly-His-Lys, bound to a copper(II) ion
Also known as	Copper tripeptide-1, prezatide copper, Cu-GHK
Molecular formula	C14H24N6O4 (GHK); C14H24CuN6O4 for the 1:1 copper complex in PubChem
Molecular weight	340.38 g/mol (GHK); about 403.9 g/mol (1:1 copper complex)
CAS number	49557-75-7 (GHK); 89030-95-5 (GHK-Cu)
First identified	1973, in human serum (Pickart and Thaler)
Main research areas	Extracellular matrix, collagen synthesis, copper transport, connective tissue repair models, gene expression
Evidence base	Mostly cell culture and rodent models
Research format	Lyophilized powder in GHK-Cu 50mg research vials
Regulatory status	Not approved by the FDA as a drug for any indication

The story starts with liver cells, not skin. In 1973, Loren Pickart and M. M. Thaler reported a tripeptide in human serum that helped normal liver cells survive longer in culture and stimulated growth in a neoplastic liver cell line (Pickart and Thaler, 1973).

That second detail tends to drop out of most summaries. The earliest observations included growth effects in a tumor-derived cell line, and the connective tissue research the compound is known for came years later.

By 1988, a group led by François-Xavier Maquart had described GHK as a plasma tripeptide with an affinity for copper(II) ions and reported its effect on collagen production in cultured fibroblasts (Maquart et al., 1988). Tucked into that paper is an observation that still shapes how people think about the peptide.

The GHK sequence sits inside the alpha-2 chain of type I collagen, and Maquart’s group proposed that proteases could release it at sites of tissue damage. If that’s right, GHK isn’t arriving from outside the tissue. It’s a fragment of collagen freed during breakdown, which is a big part of why it’s studied in connective tissue remodeling.

Five decades of research sit behind the compound now. Here are the milestones this guide draws on.

Year	Development	Model
1973	Tripeptide identified in human serum	Liver cells in culture
1980	Found bound to copper and iron in plasma; shown to increase copper uptake into cells	Plasma analysis and hepatoma cells
1988	Increased collagen synthesis reported	Cultured fibroblasts
1993	Increased connective tissue accumulation reported in vivo	Rat experimental wounds
2000	Increased MMP-2 expression reported	Cultured fibroblasts
2012	Copper-free GHK examined directly	Skin cell research
2018	Reported effects reinterpreted through gene expression data	Review of existing literature

GHK-Cu mechanism of action: how the copper binding works

GHK-Cu’s proposed mechanism of action centers on copper. The GHK peptide binds copper(II) ions (Maquart et al., 1988) and appears to work as a copper transport factor, increasing copper uptake into cells (Pickart et al., 1980). The copper is held by the peptide rather than locked on with a covalent bond, and that detail matters more than it sounds.

Nor is the pairing a lab construct. When Pickart and Thaler went back to the peptide in plasma, they reported that it’s complexed with copper and iron in vivo (Pickart and Thaler, 1980). A companion paper in Nature found it co-purifying with roughly equimolar copper (Pickart et al., 1980).

And it’s selective. At physiological pH, the 1980 work reported GHK binding copper, cobalt, iron, nickel and zinc, while showing no affinity for calcium, potassium or sodium (Pickart and Thaler, 1980).

Why copper in particular? Structure gave the Nature authors a clue, since GHK resembles the copper transport sites on albumin and alpha-fetoprotein, where copper sits on a histidine next to a basic residue. That led them to propose GHK as a copper transport factor, and they reported that it readily forms copper(II) complexes and increases copper uptake into cultured hepatoma cells (Pickart et al., 1980).

They also found that several tripeptides sharing the same histidyl-lysyl linkage were nearly as active as GHK itself. That points researchers toward the histidine-lysine pairing when thinking about how the peptide works.

For anyone designing or reading a study, the first consequence is simple. GHK and GHK-Cu aren’t interchangeable. The foundational matrix studies, including the 1988 fibroblast work, the 1993 rat wound model and the 2000 matrix metalloproteinase study, all describe their test material as the tripeptide-copper complex (Maquart et al., 1993; Siméon et al., 2000).

So a result with GHK-Cu doesn’t automatically carry over to the free peptide, and the reverse is true as well. Check which form a paper used before comparing it with another.

	GHK (free peptide)	GHK-Cu (copper complex)
Composition	Gly-His-Lys	Gly-His-Lys bound to copper(II)
Copper present	No	Yes
Form used in the 1988, 1993 and 2000 matrix studies	No	Yes
Typical research interest	Sequence origin within collagen, copper-free comparisons	Matrix synthesis and turnover, copper transport, connective tissue models

Then there’s the chemistry. Because the copper is bound rather than fixed, other molecules in a solution can compete for it, and buffers with strong chelating agents like EDTA can pull it off the complex entirely. You’d end up studying something other than what’s on the label.

Separating the peptide’s contribution from the copper’s is still an open question. Some later work has looked at copper-free GHK directly, for example in skin cell research (Choi et al., 2012), but most of the matrix literature uses the complex, so read claims about which part does what with care.

What does GHK-Cu do in research?

In laboratory research, GHK-Cu was reported to increase collagen synthesis and MMP-2 expression in fibroblast cultures, and connective tissue accumulation in rat wound models. All of it concerns the extracellular matrix, the scaffold of collagen and other proteins that holds tissue together. Most of what’s known comes from fibroblast cultures, rodent wound models and gene expression analysis, and each has limits.

Pickart’s review of GHK and tissue remodeling covers the older studies in more depth than there’s room for here (Pickart, 2008).

Collagen and extracellular matrix findings

Fibroblasts make most of the collagen in connective tissue, so they’re the obvious place to start. Maquart and colleagues reported that GHK-Cu raised collagen synthesis in fibroblast cultures, with the effect starting in the picomolar range and peaking near one nanomolar (Maquart et al., 1988).

Two details are easy to miss. None of that increase came from extra cells, so the cells were making more collagen rather than just multiplying. And the concentrations were tiny, which goes a long way toward explaining why the result held people’s attention.

Remodeling isn’t only about building matrix, though. It also needs controlled breakdown, and GHK-Cu has been studied on that side too.

Siméon and colleagues reported that the tripeptide-copper complex increased expression of matrix metalloproteinase-2 (MMP-2) in fibroblast cultures (Siméon et al., 2000). MMP-2 is an enzyme that degrades parts of the extracellular matrix.

Put those together and you get a compound that, in cell culture, touches both sides of matrix turnover. Across the wider literature, the 2018 review reports more collagen, elastin and glycosaminoglycan synthesis, plus support for dermal fibroblast function (Pickart and Margolina, 2018).

Tissue repair and wound healing models

Almost everything written about GHK-Cu and wound healing traces back to a handful of animal studies. Most often cited is a study that used experimental wound models in rats and reported that the tripeptide-copper complex stimulated connective tissue accumulation in vivo (Maquart et al., 1993).

It carries weight because it moved the question out of the culture dish and into living tissue. It’s still a rodent model, though. Rat skin differs from other species’ in structure and in how wounds close, so the result tells you what happened in that model, not what the compound does in general.

It also measured something specific. Its title names the outcome: connective tissue accumulation, meaning how much matrix got deposited in the wound.

That’s related to how fast a wound closes or how strong the repaired tissue ends up, but it isn’t the same thing. If you see this study cited for closure speed, check whether the paper actually measured it.

Skin, lung connective tissue, bone, liver, stomach lining: the 2018 review lists tissue repair findings in all of them (Pickart and Margolina, 2018). That breadth is interesting. It’s also a reason to be careful.

Results scattered across many tissues, mostly in animal and cell models, show where to look next. They don’t add up to an established profile. For the digestive tract side of that picture, see the overview of GHK-Cu gut health research.

Gene expression findings

Gene expression is the newest layer of GHK research. Pickart and Margolina’s 2018 review reinterprets the peptide’s many reported actions through gene expression data (Pickart and Margolina, 2018).

That’s a good way to generate hypotheses. It can point to the systems a compound might touch and the experiments most likely to be informative. What it can’t do on its own is tell you what the peptide does in a living organism, because a link at the expression level isn’t a measured outcome.

Keep in mind what kind of document it is, too. As a review, it draws on existing studies and datasets rather than new experiments, so it’s only as strong as the work underneath.

Nerve outgrowth also makes the review’s list of GHK’s reported actions. That’s the starting point for GHK-Cu nerve regeneration research.

Reading a GHK-Cu study critically

With a literature this heavy on cell culture and animal work, a paper is only as good as its design. Six questions will sort the useful studies from the rest.

• Which form was tested? GHK, GHK-Cu or a modified analog. Only compare papers that used the same one.
• Was there a copper-only control? Copper salts have biological effects of their own. If a study only compares GHK-Cu against an untreated control, it can’t tell you whether an effect came from the complex or from the copper. A copper salt arm at a matched copper concentration settles it.
• What was the model? Fibroblast lines, primary cells, rodent wound models and human skin explants answer different questions. The model should fit the claim.
• How was concentration reported? Molar concentrations compare cleanly across studies. Mass-based figures depend on whether the copper was counted in the weight, which muddies comparisons.
• What was actually measured? Collagen synthesis, matrix accumulation, gene expression and closure speed are four different outcomes. Make sure the conclusion matches the measurement.
• Has anyone else reproduced it? Given how concentrated this literature’s authorship is (more on that below), an independent replication counts for far more than a single result.

Where the GHK-Cu evidence is limited

GHK-Cu has a longer research history than most peptides on this site. That history comes with limits, and they’re more useful to know than another list of highlights.

Most of the evidence is preclinical. The core findings come from fibroblast cultures and rodent wound models.

Those are legitimate, informative systems. They just aren’t a substitute for controlled research in whatever context you actually care about.

Effects aren’t one-directional. The 1980 Nature paper describes GHK producing responses in cultured systems that ranged from stimulated growth and differentiation all the way to outright toxicity (Pickart et al., 1980). And the 1973 paper, remember, reported growth in a tumor-derived liver line.

Authorship is concentrated. Loren Pickart, who first described the peptide, is an author on the 1973 discovery paper, both 1980 copper studies, the 1988 fibroblast study and all three reviews cited here. The 1988 paper lists his affiliation as Procyte Corporation, a commercial entity rather than an academic lab.

That doesn’t make any of it wrong. Young fields are often built by a few groups, and the 2000 MMP-2 study and the 2012 copper-free work both came from teams without him on the author list. It does mean independent replication deserves extra weight.

Human research mostly answers different questions. Much of the work involving human skin has looked at topical formulations in cosmetic settings, as the skin-focused review literature shows (Pickart et al., 2015). That’s useful for formulation and appearance questions, not the mechanism questions laboratory research asks.

It isn’t an approved drug. GHK-Cu isn’t approved by the FDA as a drug for any indication, and research-grade material is sold for laboratory use only.

GHK-Cu in combination research: the GLOW and KLOW blends

Two blend names dominate searches around GHK-Cu. GLOW refers to GHK-Cu combined with BPC-157 and TB-500, and KLOW adds a fourth compound, KPV, another short tripeptide.

Neither name comes from the scientific literature. They’re market names for combinations, and the evidence behind each component comes from studying that compound on its own, which matters when you’re judging what a blend can and can’t tell you.

The usual rationale is that each compound probes a different part of a broader repair process. For the other two GLOW components, see the BPC-157 research guide and the thymosin beta-4 (TB-500) research guide.

Combination designs only produce interpretable results when they include single-compound arms. Without them, you can’t pin an effect on any one compound, and the study says less than it seems to. It’s the most common weakness in combination research.

Adding GHK-Cu to a mix also brings a variable that single-compound work doesn’t have. Anything else present that binds metal ions could change how much copper stays on GHK, so formulation and solvent details belong in the methods.

The GLOW peptide stack overview covers how these designs are set up and what they have and haven’t shown, at the mechanism level only. Researchers working with all three compounds can find BPC-157, TB-500 and GHK-Cu together as a single research product.

Formulation research sometimes compares GHK-Cu with retinoids instead. That’s a separate question, covered in copper peptides vs retinol.

How to store and reconstitute GHK-Cu

Research-grade GHK-Cu comes as a lyophilized powder. Keep sealed vials cold, dry and out of the light until you need them, and follow the storage conditions on the batch’s certificate of analysis.

Reconstitution turns the powder into a solution of known concentration. Use a sterile solvent, run it slowly down the inside wall of the vial, and let the powder dissolve on its own without shaking. For the full method, including the concentration math, see how to reconstitute peptides.

Solutions are less stable than dry powder, so only make what a study needs and avoid repeated freeze-thaw cycles. And since this is a copper complex, leave strong chelating agents out of your solvent unless the design calls for them.

Log the batch number, reconstitution date and solvent for every vial. When a result needs checking or repeating, you’ll be able to trace it back to the exact material.

Buying GHK-Cu for research: what to verify

Before buying any research peptide, ask what the supplier can document. For GHK-Cu, three checks cover most of it.

• Identity. Mass spectrometry confirms the molecule in the vial has the expected mass for the target compound.
• Purity. High-performance liquid chromatography (HPLC) separates a sample into its components and reports what share is the target compound.
• Batch match. The certificate of analysis should carry a batch or lot number that matches the vial, so the results describe what you actually received.

A certificate of analysis is only as good as it is specific. One with no batch number, no test date or no named testing lab doesn’t describe the vial in your hand, and it isn’t verification.

Spartan supplies GHK-Cu as a lyophilized powder in 50 mg research vials, and the GHK-Cu COA is published so you can review it before you buy. When you’re ready to source material, you’ll find the GHK-Cu copper peptide on the product page.

GHK-Cu research summary

GHK-Cu is a copper-binding tripeptide with a five-decade research record, most of it in cell culture and rodent models. The strongest findings are increased collagen synthesis in fibroblasts and increased connective tissue accumulation in rat wound models, alongside early evidence that it binds and transports copper.

The limits are just as clear: concentrated authorship, a mostly preclinical evidence base and no FDA approval for any indication. Read on their own terms, the studies give laboratory researchers a well-defined place to start.

Frequently asked questions

What is GHK-Cu?

GHK-Cu is a copper peptide: the tripeptide glycine-histidine-lysine bound to a copper(II) ion. It was first identified in human serum in 1973, and laboratory research studies its effects on the extracellular matrix and connective tissue in cell culture and animal models.

What does GHK-Cu do in laboratory research?

In cultured fibroblasts, GHK-Cu increased collagen synthesis at picomolar to nanomolar concentrations and increased expression of MMP-2, an enzyme that breaks down matrix. In rat wound models it increased connective tissue accumulation. These are preclinical findings, not established outcomes in humans.

What is GHK-Cu used for?

In laboratory research, GHK-Cu is used to study extracellular matrix remodeling, collagen and glycosaminoglycan synthesis, copper transport into cells and connective tissue repair in animal models. It isn’t approved for any medical use.

What does the copper in GHK-Cu do?

Early work found GHK bound to copper in plasma and proposed that it acts as a copper transport factor, reporting that it increases copper uptake into cultured cells. The copper complex is also the form used in the foundational matrix studies. How much of any given effect comes from the peptide and how much from the copper is still an open question.

Is GHK-Cu the same as GHK?

No. GHK is the free tripeptide and GHK-Cu is the same tripeptide bound to copper. Results from one form don’t automatically apply to the other.

What are the GLOW and KLOW peptide blends?

GLOW is a market name for GHK-Cu combined with BPC-157 and TB-500. KLOW adds KPV, another short tripeptide. Neither name comes from the scientific literature, and the evidence behind each component comes from studying that compound on its own.

How should GHK-Cu be stored for laboratory research?

Keep lyophilized vials sealed, cold, dry and away from light, following the conditions on the batch’s certificate of analysis. Solutions are less stable than the powder, so only reconstitute what a study needs.

What should a certificate of analysis for GHK-Cu show?

At a minimum: identity confirmation by mass spectrometry, purity by HPLC, and a batch or lot number that matches the vial.

Is GHK-Cu FDA approved?

No. GHK-Cu isn’t FDA approved as a drug for any indication, and research-grade GHK-Cu is sold for laboratory research use only.

Research use disclaimer. All content published by Spartan Peptides is for educational and research purposes only. It is not medical advice and is not a recommendation for human use. Products sold on this site are research compounds intended for laboratory and in vitro applications only.